1. Indications and Usage
\nPulmonary Arterial Hypertension (PAH): Indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH, WHO Group 1) to delay disease progression.
\nIt is used for the treatment of adult pulmonary arterial hypertension (PAH, WHO Group 1) to delay disease progression (including death, intravenous or subcutaneous injection of prostaglandins, or clinical deterioration of PAH).
\n2. Dosage and Administration
\nAdministration: Oral administration, once daily. Can be taken with or without food. Tablets must be swallowed whole; do not chew, split, or crush.
\nDose: The recommended dose is 10 mg once daily.
\nPregnancy Testing: For females of reproductive potential, pregnancy testing is required prior to initiation and monthly during treatment.
\n3. Mechanism of Action
\nEndothelin Receptor Antagonist (ERA): Macitentan is a dual endothelin receptor antagonist (ETA and ETB).
\nPathway: It competitively binds to ETA and ETB receptors with high affinity and tissue retention, blocking the vasoconstrictive and proliferative effects of endothelin-1 (ET-1). This leads to pulmonary and systemic vasodilation and inhibition of vascular remodeling.
\n4. Safety and Warnings
\nEmbryo-Fetal Toxicity: Contraindicated in pregnancy. Macitentan may cause fetal harm. Effective contraception is mandatory during treatment and for at least one month after the last dose.
\nHepatotoxicity: Elevations in liver transaminases (ALT\/AST) have been observed. Liver function tests (LFTs) must be performed prior to initiation and subsequently as clinically indicated (e.g., monthly).
\nFluid Retention: Peripheral edema and fluid retention are known side effects. Monitor for signs of decompensated heart failure.
\nDecrease in Hemoglobin: Dose-dependent reduction in hemoglobin may occur; monitor hemoglobin levels.
\n5. Adverse Reactions
\nMost Common: Anaemia, nasopharyngitis, headache, influenza, diarrhea, bronchitis, rash, pruritus, and fatigue.
\n6. Drug Interactions
\nCYP3A4 Inhibitors: Strong inhibitors (e.g., ketoconazole) may increase macitentan exposure.
\nCYP3A4 Inducers: Strong inducers (e.g., rifampicin) may significantly decrease macitentan exposure and efficacy; concomitant use is not recommended.
\nHormonal Contraceptives: May reduce the efficacy of hormonal contraceptives; alternative non-hormonal methods are recommended.
\n7. Pharmaceutical Information
\nChemical Name: N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N’-propylsulfamide.<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u50b2\u6734\u8212\u00ae (Opsumit\u00ae)
\nGeneric Name: Macitentan
\nStrength: 10 mg per film-coated tablet, 30 tablets per box
\nManufacturer: Excella GmbH & Co. KG (Germany)
\nMarketing Authorization Holder: Actelion Pharmaceuticals Ltd\uff08\u7231\u53ef\u6cf0\u9686\uff09\uff1b\u5883\u5185\u8d23\u4efb\u4eba\uff1a\u897f\u5b89\u6768\u68ee\u5236\u836f\u6709\u9650\u516c\u53f8
\nApproval Date in China: September 29, 2017
\nRegistration Number: \u56fd\u836f\u51c6\u5b57HJ20170376
\nStorage: Store below 30\u2103, protect from moisture; keep in the original blister packaging, keep out of sight and reach of children<\/p>\n
Price&Cost:Contact Us now for the best price of Macitentan\uff08Opsumit\uff09<\/p>\n","protected":false},"featured_media":3076,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[27],"product_tag":[],"class_list":["post-3073","product","type-product","status-publish","has-post-thumbnail","product_cat-tablets","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n